Microsoft To Reprogram Diseased Cells To 'Solve' Cancer

Microsoft Corporation (NASDAQ:MSFT) recently announced that it intends to “solve” cancer within the next decade by the use of computer programming.

Microsoft’s Take on Cancer

Just like a virus affected PC requires an antivirus to debug it, Microsoft is planning to take on the disease of cancer by reprogramming the diseased cells into healthy cells.

In other words, Microsoft is planning to develop a chip made of human DNA that can be placed inside the cells. It can then identify the diseased cells and then get rid of the same by rebooting the computer.

In order to achieve the desired results, Microsoft has already started roping in some of the best biologists from all over the world who will work at its laboratory in the UK.

Competition

We note that there is fierce competition in the oncology space with the presence of major tech players such as International Business Machines Corporation (NYSE:IBM) and Alphabet Inc. (NASDAQ:GOOGL) owned Google. While IBM with its Watson Oncology project is working on targeted medicine, Microsoft’s attempt to develop a programmable cell will be the first of its kind.

Moreover, following the footprint of Google’s DeepMind, which has played a pivotal role in the treatment of neck and head cancers, Microsoft intends to use artificial intelligence in radiology through the use of machine vision tools to analyze CT scans for tumors.

Our Take

Though the cure for the ‘king of maladies’ could take some time to develop and reach the masses, Microsoft’s approach toward the disease is unique and holds promise.

MICROSOFT CORP Price

MICROSOFT CORP Price | MICROSOFT CORP Quote

Zacks Rank & Key Picks

At present, Microsoft carries a Zacks Rank #3 (Hold).

A better-ranked stock in the broader technology space is Avid Technology, Inc. (NASDAQ:AVID) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>